Due to delays in global regulatory approvals of the manufacturing site, Pegylated Interferon alfa2a (Pegasys) is anticipated to be of possible critical supply by 1 June 2025. Please refer to https://apps.tga.gov.au/prod/MSI/search/ for TGA updates on its shortage.

HSANZ advises prescribers and consumer communities to begin open conversations discussing personalised strategies to maximise and optimise current Pegasys supply, while minimising loss of disease control. Prescribers may need to consider avoiding starting new patients on Pegasys until the supply issue is resolved. If you have ongoing patients on Pegasys it may be necessary to have a back-up plan in case the supply becomes critical.

HSANZ MPN Specialist leads as the largest haematology group prescribers of Pegasys have begun discussions and coordination of mitigative strategies to maximise utility of prescribed supply of Pegasys.  A video link is availale here where Dr Cecily Forsyth discusses possible strategies to consider in your practice.  

Please note that patients should be strongly encouraged to discuss with their primary haematologists before utilising any change to their prescription or delivery.

HSANZ has begun to disseminate and share this information to the wider range of prescribers with various partner organisations.  We encourage members to refer to the HSANZ news page for pertinent up to date information about this anticipated shortage. We would encourage close engagement with your respective state MPN and CTCL leads for any additional advice. In addition please feel free to forward any immediate queries to hsanz@hsanz.org.au and we will facilitate communication and connection.

Thank you.

A/Prof Hui-Peng Lee

HSANZ President